Mycophenolate mofetil in dysimmune neuropathies: A preliminary study

Muscle and Nerve

Volumn 29, Issue 5, 2004, Pages 748-749

  Benedetti, Luana ^a   Grandis, Marina ^a   Nobblo, Lucilla ^a   Beronlo, Alessandro ^a   Ghiglione, Elisabetta ^a   Manzino, Marcello ^b   Primavera, Alberto ^a   Mancardi, Glanluigi ^a   Schenone, Angelo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b San Paolo Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABDOMINAL PAIN; AMYLASE BLOOD LEVEL; ANOREXIA; BODY WEIGHT DISORDER; DISEASE EXACERBATION; DRUG EFFICACY; DYSIMMUNE NEUROPATHY; HUMAN; LETTER; LEUKOPENIA; NEUROPATHY; PRIORITY JOURNAL; RELAPSE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

HUMANS; MYCOPHENOLIC ACID; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 2442613121     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.20024     Document Type: Letter

References (11)

1. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanism of action. Immunopharmacology 2000;47:85-118.
2. Chaudry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56: 94-96.
3. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97-99.
4. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999;8:731-736.
5. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, Van Doorn P, Dalakas M, Bojar M, Swan A, and the Inflammatory Neuropathy Cause and Treatment (IN-CAT) Group. Randomized controlled trial of intravenous immunoglobulin versus oral prednilosone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
6. Kleyweg RP, van der Mechè FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103-1109.
7. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (Cell-cept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185:119-122.
8. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-324.
9. Trotti A, Colevas AD, Setser A, Rush V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181.
10. Umapathi T, Hughes R. Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 2002;9:683-685.
11. Van den Berg-Vos RM, Franssen H, Wokke JHJ, Van Es HW, Van den Berg LH. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol 2000;48:919-926.